GlassScriptPhysician profile
Darlene S Bisgaard
NPI 1982633657
$2,200.51
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,062 · 2022: $139.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $426.25 | 2021 | |
| Vyne Pharmaceuticals INC. | $311.82 | 2021 | |
| Janssen Biotech, INC. | $275.10 | 2021 | |
| Lilly USA, LLC | $205.42 | 2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $181.82 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $181.22 | 2021 | |
| Almirall LLC | $123.20 | 2022 | |
| Pfizer INC. | $102.90 | 2021 | |
| Incyte Corporation | $81.37 | 2021 | |
| Genzyme Corporation | $54.53 | 2021 | |
| Novartis Pharmaceuticals Corporation | $53.67 | 2021 | |
| Leo Pharma INC. | $42.69 | 2021 | |
| Galderma Laboratories, L.P. | $40.58 | 2021 | |
| Dermira, INC. | $31.52 | 2021 | |
| Janssen Scientific Affairs, LLC | $20.70 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $17.64 | 2021 | |
| Amgen INC. | $16.77 | 2021 | |
| Sanofi-Aventis U.S. LLC | $16.75 | 2021 | |
| Nabriva Therapeutics, Plc | $16.56 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darlene Bisgaard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.